• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.05% Nasdaq Down1.14%

    Valeant Pharmaceuticals International, Inc. (VRX)

    -NYSE
    34.59 Up 1.94(5.94%) 11:57AM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Valeant Pharmaceuticals International, Inc.
    2150 St. Elzéar boulevard West
    Laval, QC H7L 4A8
    Canada - Map
    Phone: 514-744-6792
    Fax: 514-744-6272
    Website: http://www.valeant.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Delivery
    Full Time Employees:16,800

    Business Summary 

    Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Valeant Pharmaceuticals International, Inc.

    Corporate Governance 
    Valeant Pharmaceuticals International, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 2. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 1.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. J. Michael Pearson , 57
    Chief Exec. Officer and Director
    2.77M0.00
    Mr. Robert L. Rosiello ,
    Chief Financial Officer and Exec. VP
    7.27M0.00
    Dr. Ari S. Kellen , 53
    Exec. VP and Company Group Chairman
    4.73M0.00
    Ms. Anne Clem Whitaker , 49
    Exec. VP and Group Chairman
    1.62M0.00
    Dr. Robert F. Butz ,
    VP of Medical & Scientific Affairs
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders